Detection of minimal residual disease in acute leukemia patients

Cytokines and Molecular Therapy

Volumn 2, Issue 4, 1996, Pages 121-133

  Van Dongen, Jjm ^a   Szczepanski, T ^a   De Bruijn, Mac ^a   Van Den Beemd, Mwm ^a   De Bruin Versteeg, S ^a   Wijkhuijs, J M ^a   Tibbe, Gjm ^a   Van Gastel Mol, E J ^a   Groeneveld, K ^a   Hooijkaas, H ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Aberrant immunophenotypes; Acute leukemia; Chromosome aberrations; Flow cytometry; Immunoglobulin (ig) genes; Junctional regions; Minimal residual disease (MRD); Polymerase chain reaction (PCR); T cell receptor (TcR) genes

Indexed keywords

TUMOR MARKER;

ACUTE LEUKEMIA; ARTICLE; CANCER IMMUNOLOGY; CHROMOSOME ABERRATION; DNA SEQUENCE; FLOW CYTOMETRY; GENE REARRANGEMENT; HUMAN; HUMAN CELL; IMMUNOGLOBULIN GENE; IMMUNOPHENOTYPING; MINIMAL RESIDUAL DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; T LYMPHOCYTE RECEPTOR GENE;

ACUTE DISEASE; CHROMOSOME ABERRATIONS; GENE REARRANGEMENT; GENE REARRANGEMENT, T-LYMPHOCYTE; GENES, IMMUNOGLOBULIN; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 0029795242     PISSN: 13556568     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Van Dongen JJM, Wolvers-Tettero ILM, Analysis of immunoglobulin and T cell receptor genes. Part II: possibilities and limitations in the diagnosis and management of lymphoproliferative diseases and related disorders. Clin Chim Acta (1991) 198: 93-174.
2. Freireich EJ, Cork A, Stass SA et al, Cytogenetics for detection of minimal residual disease in acute myeloblastic leukemia. Leukemia (1992) 6: 500-6.
3. Heerema NA, Argyropoulos G, Weetman R et al, Interphase in situ hybridization reveals minimal residual disease in early remission and return of the diagnostic clone in karyotypical normal relapse of acute lymphoblastic leukemia. Leukemia (1993) 7: 537-43.
4. Nylund SJ, Ruutu T, Saarinen U et al, Detection of minimal residual disease using fluorescence DNA in situ hybridization: a follow-up study in leukemia and lymphoma patients. Leukemia (1994) 8: 587-94.
5. Van Dongen JJM, Hooijkaas H, Adriaansen HJ et al, Detection of minimal residual acute lymphoblastic leukemia by immunological marker analysis: possibilities and limitations. In Minimal residual disease in acute leukemia (ed A Hagenbeek, B Löwenberg), 113-33. M Nijhoff, Dordrecht, 1986.
6. Van Dongen JJM, Breit TM, Adriaansen HJ et al, Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction. Leukemia (1992) 6S1: 47-59.
7. Ito Y, Miyamura K, Clinical significance of minimal residual disease in leukemia detected by polymerase chain reaction: is molecular remission a milestone for achieving a cure? Lettk Lymphoma (1994) 16: 57-64.
8. Campana D, Pui C-H, Detection of minimal residual disease in acute leukemia: méthodologie advances and clinical significance. Blood (1995) 85: 1416-34.
9. Smith RG, Kitchens RL, Phenotypic heterogeneity of TDT+ cells in the blood and bone marrow: implications for surveillance of residual leukemia. Blood (1989) 74: 312-19.
10. Campana D, Coustan-Smith E, Janossy G, The immunological detection of minimal residual disease in acute leukemia. Blood (1990) 76: 163-71.
11. Macedo A, Orfao A, Ciudad J et al, Phenotypic analysis of CD34 subpopulations in normal human bone marrow and its application of the detection of minimal residual disease. Leukemia (1995) 9: 1896-901.
12. Terstappen LWMM, Loken MR, Five-dimensional flow cytometry as a new approach for blood and bone marrow differentials. Cytometry (1988) 9: 548-56.
13. Groeneveld K, Te Marvelde JG, Van den Beemd MWM et al, Flow cytometric detection of intracellular antigens for immunophenotyping of normal and malignant leukocytes. Leukemia, in press.
14. Knulst AC, Adriaansen HJ, Hählen K et al, Early diagnosis of smoldering acute lymphoblastic leukemia using immunological marker analysis. Leukemia (1993) 7: 532-6.
15. Farahat H, Lens D, Zomas A et al, Quantitative flow cytometry can distinguish between normal and leukaemic B-cell precursor. Br J Haematol (1995) 91: 640-6.
16. Smedmyr B, Bengtsson M, Jakobsson A et al, . Regeneration of CALLA (CD10+), TdT and double-positive cells in the bone marrow and blood after autologous bone marrow transplantation. EnrJ Haematol (1991) 46: 146-51.
17. Drach J, Drach D, Glassl H et al, Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease. Cytometry (1992) 13: 893-901.
18. Hurwitz CA, Gore SD, Stone KD, Civin CI, Flow cytometric detection of rare normal human marrow cells with immunophenotypes characteristic of acute lymphoblastic leukemia cells. Leukemia (1992) 6: 233-9.
19. Behm FG, Smith FO, Raimondi SC et al, Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4; 11) (q21; q23) or t(ll; 19) (q23; p!3) and MLLgene rearrangements. 5/00-4(1996) 87: 1134-9.
20. Smith FO, Rauch C, Williams DE et al, The human homologue of rat NG2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor-prognosis patients with abnormalities of chromosome band Ilq23. Blood (1996)87: 1123-33.
21. Reading CL, Estey EH, Huh YO et al, Expression of unusual immunophenotype combinations in acute myelogenous leukemia. Blood (1993) 81: 3083-90.
22. Macedo A, Orfao A, Gonzalez M et al, Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: implications for minimal residual disease studies. Leukemia (1995) 9: 993-8.
23. Macedo A, Orfao A, Martinez A et al, Immunophenotype of c-kit cells in normal human bone marrow: implications for the detection of minimal residual disease in AML. Br J Haematol (1995) 89: 338-41.
24. Adriaansen HJ, Jacobs BC, Kappers-Klunne MC et al, Detection of residual disease in AML patients by use of double immunological marker analysis for terminal deoxynucleotidyl transferase and myeloid markers. Leukemia (1993) 7: 472-81.
25. Macedo A, San Miguel JF, Vidriales MB et al, Phenotypic changes in acute myeloid leukaemia: implications in the detection of minimal residual disease. J Clin Palhol (1996) 49: 15-18.
26. Beishuizen A, Verhoeven M-AJ, Mol EJ, Van Dongen JJM, Detection of immunoglobulin kappa light-chain gene rearrangement patterns for Southern blot analysis. Leukemia (1994) 8: 2228-36.
27. Beishuizen A, Van Wering ER, Breit TM et al, Molecular biology of acute lymphoblastic leukemia: implications for detection of minimal residual disease. In: Acme lenkemias V (ed W Hiddeman, TH Büchner, B Wörmann) 460-74. Springer-Verlag, Berlin, 1996.
28. Adriaansen HJ, Soeting PWC, Wolvers-Tettero ILM, Van Dongen JJM, Immunoglobulin and T-cell receptor gene rearrangements in acute non-lymphocytic leukemias: analysis of 54 cases and a review of the literature. Leukemia (1991) 5: 744-51.
29. Sânchez I, San Miguel JF, Corral J et al, Gene rearrangement in acute non-lymphoblastic leukaemia: correlation with morphological and immunophenotypic characteristics of blast cells. Er J Haematol (1995) 89: 104-9.
30. Breit TM, Van Dongen JJM, Unravelling human Tcell receptor junctional region sequences. Thymus (1994) 22: 177-99.
31. Beishuizen A, Hählen K, Hagemaijer A et al, Multiple rearranged immunoglobulin genes in childhood acute lymphoblastic leukemia of precursor-B-cell origin. Leukemia (1991) 5: 657-67.
32. Beishuizen A, Verhoeven M-AJ, Van Wering ER et al, Analysis of immunoglobulin and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by PCR analysis. Blood (1994} 83: 2238-47.
33. Ghali DW, Panzer S, Fischer S et al, Heterogeneity of the T-cell receptor ôgene indicating subclone formation in acute precursor B-cell leukemias. Blood (1995) 85: 2795-801.
34. Steward CG, Goulden NJ, Katz F et al, A polymerase chain reaction study of the stability of Ig heavy-chain and T-cell receptor 8 gene rearrangements between presentation and relapse of childhood B-lineage acute lymphoblastic leukemia. Blood (1994) 83: 1355-62.
35. Taylor JJ, Rowe D, Kylefjord H et al, Characterisation of non-concordance in the T-cell receptor y chain genes at presentation and clinical relapse in acute lymphoblastic leukemia. Leukemia (1994) 8: 60-6.
36. Baruchel A, Cayuela J-M, Macintyre E et al, Assessment of clonal evolution at Ig/TCR loci in acute lymphoblastic leukaemia by single-strand conformation polymorphism studies and highly résolutive PCR derived methods: implications for a general strategy of minimal residual disease detection. Br3 Haematol (1995) 90: 85-93.
37. Marshall GM, Kwan E, Habler M et al, Characterization of clonal immunoglobulin heavy chain and T cell receptor -y gene rearrangements during progression of childhood acute lymphoblastic leukemia. Leukemia (1995) 9: 1847-50.
38. Steenbergen EJ, Verhagen OJ, Van Leeuwen EF et al, Prolonged persistence of PCR-detectable minimal residual disease after diagnosis of first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia. Leukemia (1995) 9: 1726-34.
39. Biondi A, Yokota S, Hansen-Hagge TE et al, Minimal residual disease in childhood acute lymphoblastic leukemia: analysis of patients in continuous complete remission or with consecutive relapse. Leukemia (1992) 6: 282-8.
40. Ito Y, Wasserman R, Galili N et al, . Molecular residual disease status at the end of chemotherapy fails to predict subsequent relapse in children with B-lineage acute lymphoblastic leukemia. J Clin OucoJ (1993) 11: 546-53.
41. Neale GAM, Menarguez J3 Kitchingman GR et al, Detection of minimal residual disease in T-cell acute lymphoblastic leukemia using polymerase chain reaction predicts impending relapse. Blood (1991) 78: 739-47.
42. Nizet Y, Martiat P, Vaerman JL et al, Follow-up of residual disease (MRD) in B lineage acute leukemias using a simplified PCR strategy: evolution of MRD rather than its detection is correlated with clinical outcome. Br J Haematol (1991) 79: 205-10.
43. Nizet Y, Van Daele S, Lewalle P et al, Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogeneic IgH probes and the polymerase chain reaction. 5/oorf(1993) 82: 1618-25.
44. Wasserman R, Galili N, Ito Y et al, Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia. J Clin Oncol (1992) 10: 1879-88.
45. Yamada M, Wasserman R, Lange B et al, Minimal residual disease in childhood B-lineage lymphoblastic leukemia: persistence of leukemic cells during the first 18 months of treatment. N Engl J Med (1990) 323: 448-55.
46. Yokota S, Hansen-Hagge TE, Ludwig W-D et al, Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients. Blood (1991) 77: 331-9.
47. Brisco MJ, Condon J, Hughes E et al, Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet (1994) 343: 196-200.
48. Cave H, Guidai C, Rohrlich P et al, Prospective monitoring and quamitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of 8 and y T-cell receptor genes. Blood (1994) 83: 1892-902.
49. Goulden N, Langlands K, Steward C et al, PCR assessment of bone marrow status in 'isolated' extramedullary relapse of childhood B-precursor acute lymphoblastic leukaemia. BrJ Haematol (1994) 87: 282-5.
50. Kitchingman GR, Residual disease detection in multiple follow-up samples in children with acute lymphoblastic leukemia. Leukemia (1994) 8: 395-401.
51. Seriu T, Yokota S, Nakao M et al, Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation. Leukemia (1995) 9: 615-23.
52. Cortes JE, Kantarjian HM, Acute lymphoblastic leukemia: a comprehensive review with emphasis on biology and therapy. Cancer (1995) 76: 2393-417.
53. Copelan EA, McGuire EA, The biology and treatment of acute lymphoblastic leukemia in adults. Blood (1995) 85: 1151-68.
54. Schölten C, Födinger M, Mitterbauer M et al, Kinetics of minimal residual disease during induction/consolidation therapy in standard-risk adult Blineage acute lymphoblastic leukemia. Ann Hematol (1995) 71: 155-60.
55. Van Dongen JJM, Adriaansen HJ, Immunobiology of leukemia. In: Leukemia, 6th edn (ed ES Henderson, TA Lister, MF Greaves) 83-130. WB Saunders, Philadelphia, 1996.
56. Breit TM, Mol EJ, Wolvers-Tettero ILM, Ludwig W-D et al, Site-specific deletions involving the tal-1 and sil genes are restricted to cells of the T-cell receptor aβ lineage: T-cell receptor 8 gene deletion mechanism affects multiple genes. J Exp Med (1993) 177: 965-77.
57. Breit TM, Beishuizen A, Ludwig W-D et al, tal-1 deletions in T-cell acute lymphoblastic leukemia as PCR target for detection of minimal residual disease. Leukemia (1993) 7: 2004-11.
58. Râbbitts TH, Chromosomal translocations in human cancer. Nature (1994) 372: 143-9.
59. Drexler HG, Borkhardt A, Janssen JWG, Detection of chromosomal translocations in leukemia-lymphoma cells by polymerase chain reaction. Lenk Lymphoma (1995) 19: 359-80.
60. Hébert J, Cayuela J-M, Daniel M-T et al, Detection of minimal residual disease in acute myelomonocytic leukemia with abnormal marrow eosinophils by nested polymerase chain reaction with allele specific amplification. Blood (1994) 84: 2291-6.
61. Privitera E, Rivolta A, Ronchetti D et al, Reverse transcriptase/polymerase chain reaction follow-up and minimal residual disease detection in t(l; 19)-positive acute lymphoblastic leukaemia. BrJ Haematol (1996) 92: 653-8.
62. Shurtleff SA, Buijs A, Behm FG et al, TELIAML1 fusion resulting from a cryptic t(12; 21) is the most common genetic lesion in pédiatrie ALL and defines a subgroup of patients with an excellent prognosis. Leukemia (1995) 9: 1985-9.
63. Romana SP, Poirel H, Leconiat M et al, High frequency of t(12; 21) in childhood B-lineage acute lymphoblastic leukemia. Blood (1995) 86: 4263-9.
64. Biernaux C, Loos M, Sels A et al, Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood (1995) 86: 3118-22.
65. Miyamura K, Tanimoto M, Morishima Y et al, Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction: possible eradication of minimal residual disease by marrow transplantation. Blood (1992) 79: 1366-70.
66. Roberts WM, Rivera GK, Raimondi SC et al, Intensive chemotherapy for Philadelphia-chromosome-positive acute lymphoblastic leukaemia. Lancet (1994) 343:331-2.
67. Mitterbauer G, Födinger M, Scherrer R et al, PCRmonitoring of minimal residual leukaemia after conventional chemotherapy and bone marrow transplantation in BCR-ABL-positive acute lymphoblastic leukaemia. Br J Haematol (1995) 89: 937-41.
68. Janssen JWG, Ludwig W-D, Borkhardt A et al, Prepre-B acute lymphoblastic leukemia: high frequency of alternatively spliced ALL1-AF4 transcripts and absence of minimal residual disease during complete remission. Blood (1994) 84: 3835-42.
69. Cimino G, Elia L, Rivolta A et al, Clinical relevance of residual disease monitoring by polymerase chain reaction in patients with ALL-l/AF-4 positive-acute lymphoblastic leukaemia. Br J Haematol (1996) 92: 659-64.
70. Diverio D, Pandolfi PP, Biondi A et al, Absence of reverse transcription-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long-term remission. Blood (1993) 82: 3556-9.
71. Huang W, Sun G-L, Li X-S et al, Acute promyelocytic leukemia: clinical relevance of two major PMLRARa isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. Blood (1993) 82: 1264-9.
72. Laczika K, Mitterbauer G, Korninger L et al, Rapid achievement of PML-RARa polymerase chain reaction (PCR)-negativity by combined treatment with all-fras-retinoic acid and chemotherapy in acute promyelocytic leukemia: a pilot study. Leukemia (1994) 8: 1-5.
73. Lo Coco F, Awisati G, Diverio D et al, Molecular evaluation of response to all-Jram-retinoic acid therapy in patients with acute promyelocytic leukemia. Blood (199 \) 77: 1657-9.
74. Lo Coco F, Diverio D, Pandolfi PP et al, Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet (1992) 340: 1437-8.
75. Miller Jr WH, Levine K, DeBlasio A et al, Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-a fusion mRNA. Blood (1993) 82: 1689-94.
76. Takatsuki H, Umemura T, Sadamura S et al, Detection of minimal residual disease by reverse transcriptase polymerase chain reaction for the PML/RARct fusion mRNA: a study in patients with acute promyelocytic leukemia following peripheral stem cell transplantation. Leukemia (1995) 9: 889-92.
77. Martinelli G, Remiddi C, Visani G et al, Molecular analysis of PML-RARa fusion mRNA detected by reverse transcription-polymerase chain reaction assay in long-term disease-free acute promyelocytic leukaemia patients. Br J Haematol (1995) 90: 966-8.
78. Fukutani H, Naoe T, Ohno R et al, Prognostic significance of the RT-PCR assay of PML-RARA transcripts in acute promyelocytic leukemia. Leukemia (1995) 9: 588-93.
79. Nucifora G, Larson RA, Rowley JD, Persistence of the 8; 21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood (1993) 82: 712-15.
80. Kusec R, Laczika K, Knöbl P et al, AMLIIETO fusion mRNA can be detected in remission blood samples of all patients with t(8; 21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia (1994) 8: 735-9.
81. Nucifora G, Rowley JD, The AML1 and ETO genes in acute myeloid leukemia with a t(8; 21). Lenk Lymphoma (1994) 14: 353-62.
82. Satake N, Maseki N, Kozu T et al, . Disappearance of AMLl-MTGS(ETO) fusion transcript in acute myeloid leukaemia patients with t (8; 21) in long-term remission. Br J Haematol (1995) 91: 892-8.
83. Martens AC, Schultz FW, Hagenbeek A, Nonhomogeneous distribution of leukemia in the bone marrow during minimal residual disease. Blood (1987) 70: 1073-8.
84. Van Dongen JJM, San Miguel JF, Techniques for detection of minimal residual disease in leukemia patients. In: 'Meet the Expert' Sessions of the Second EHA (ed European School of Haematology) 39-46. Blackwell, Oxford, 1996.